"The voice for cancer physicians and their patients in Massachusetts."

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 
  • 18 Jun 2019 12:01 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda; Merck) for patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. Read full press release. 

  • 11 Jun 2019 9:06 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved pembrolizumab (Keytruda; Merck) for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC). Read full press release. 

  • 10 Jun 2019 2:06 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted accelerated approval to polatuzumab vedotin-piiq (Polivy; Genentech), a CD79b-directed antibody-drug conjugate indicated in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies. Read full press release.

  • 05 Jun 2019 11:51 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved the addition of overall survival data in labeling for gilteritinib (Xospata; Astellas) indicated for adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. Read full press release. 

  • 28 May 2019 8:02 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved alpelisib (Piqray; Novartis) in combination with fulvestrant for postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen. Read full press release. 

  • 16 May 2019 8:48 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved Herzuma (trastuzumab-pkrb; Celltrion) as a biosimilar to Herceptin (trastuzumab; Genentech) for patients with HER2-overexpressing breast cancer. Read full press release.

  • 16 May 2019 8:24 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved ado-trastuzumab emtansine (Kadcyla; Genentech) for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. Read full press release. 

  • 16 May 2019 8:14 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved venetoclax (Venclexta; AbbVie and Genentech) for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Read full press release. 

  • 13 May 2019 7:36 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved ramucirumab (Cyramza; Lilly) as a single agent for hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP of  ≥ 400 ng/mL and have been previously treated with sorafenib. Read full press release.

  • 22 Apr 2019 1:39 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved pembrolizumab (Keytruda; Merck) plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). Read full press release. 

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 

Upcoming events

Massachusetts Society of Clinical Oncologists (c)

P.O. Box 549154, Waltham, MA, 02454
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software